PROCEPT BioRobotics (NASDAQ:PRCT) Hits New 52-Week Low – Here’s Why

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares hit a new 52-week low on Thursday . The company traded as low as $27.84 and last traded at $27.93, with a volume of 1355004 shares changing hands. The stock had previously closed at $28.40.

Analysts Set New Price Targets

Several research analysts have recently weighed in on PRCT shares. TD Cowen reduced their price target on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Truist Financial cut their price objective on shares of PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Leerink Partners reiterated an “outperform” rating and set a $55.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. BTIG Research reissued a “neutral” rating on shares of PROCEPT BioRobotics in a research note on Tuesday, September 16th. Finally, Oppenheimer upgraded PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a report on Tuesday, September 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $59.78.

PROCEPT BioRobotics Trading Up 7.1%

The company has a market cap of $1.67 billion, a P/E ratio of -19.52 and a beta of 0.98. The business’s 50-day moving average price is $34.18 and its 200 day moving average price is $45.96. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.20 and a current ratio of 8.44.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The business had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. During the same period last year, the business posted ($0.40) EPS. PROCEPT BioRobotics’s revenue was up 42.6% on a year-over-year basis. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several institutional investors and hedge funds have recently modified their holdings of the stock. BI Asset Management Fondsmaeglerselskab A S acquired a new position in PROCEPT BioRobotics in the 1st quarter valued at about $40,000. Vega Investment Solutions boosted its holdings in shares of PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after acquiring an additional 265 shares during the period. JTC Employer Solutions Trustee Ltd bought a new stake in shares of PROCEPT BioRobotics during the third quarter worth approximately $30,000. CWM LLC grew its position in shares of PROCEPT BioRobotics by 69.5% in the first quarter. CWM LLC now owns 873 shares of the company’s stock valued at $51,000 after purchasing an additional 358 shares during the last quarter. Finally, AlphaQuest LLC increased its stake in shares of PROCEPT BioRobotics by 1,262.5% during the second quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after purchasing an additional 1,010 shares during the period. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).